Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Primary Myelofibrosis 4Neoplasms 3Myeloproliferative Disorders 2Leukemia, Myeloid, Acute 2Triple Negative Breast Neoplasms 1Thrombocythemia, Essential 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Ovarian Neoplasms 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Melanoma 1Leukemia, Myelomonocytic, Chronic 1

Interventions

fludarabine 19Cyclophosphamide 19fludarabine phosphate 16Azacitidine 14Tacrolimus 13Melphalan 13venetoclax 10Cytarabine 10Busulfan 10Whole-Body Irradiation 9Thiotepa 9Mycophenolic Acid 9Stem Cell Transplantation 7Peripheral Blood Stem Cell Transplantation 7Decitabine 7decitabine and cedazuridine drug combination 6Methotrexate 6Granulocyte Colony-Stimulating Factor 6Specimen Handling 5Sirolimus 5CPX-351 5AP 1903 reagent 5thymoglobulin 4Vorinostat 4Mesna 4Injections 4Daunorubicin 4Biopsy 4Ipilimumab 3Filgrastim 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Myelodysplastic Syndromes × navitoclax × Clear all
NCT05455294 2026-01-28

Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms

Dana-Farber Cancer Institute

Phase 1 Active not recruiting
16 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡